Chemicon licenses ReNcell line and media
UK stem-cell therapeutics firm ReNeuron has signed an agreement with Chemicon International, a subsidiary of the USA's Serologicals Corp, whereby the latter will exclusively manufacture and distribute two of the former's patented ReNcell neural stem cell lines worldwide for research purposes.
Under the terms of this multi-year deal, Chemicon will exclusively manufacture and supply ReNeuron's ReNcell CX and ReNCell VM cell lines and media to the worldwide stem cell research community through its direct sales team in North America, Australia, the UK and much of Europe, as well as through its global network of distributors while, ReNeuron will receive upfront and royalty payments on all sales made by Chemicon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze